{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-011633","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.379706+00:00","generated_at":"2026-06-05T02:35:20.586610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuwellis Q4 revenue record $2.6M (+9% YoY); net loss $7.9M on financing costs; pediatric sales up 35%","bullets":["Q4 revenue $2.6M (+9% YoY); full year revenue $8.9M (+4% YoY).","Net loss attributable to common $7.9M ($2.24/share) includes $4.4M financing-related charges; prior year net loss $1.9M.","Pediatric revenue +35% YoY in Q4; utilization +28%, console sales +49%, 4 new accounts added.","Cash $3.8M, no debt; CEO targets 40% cash-burn reduction and expects capital raise in 2024.","New products launched: 12cm dELC catheter, Quelimmune pediatric device; IDE submission for Vivian device planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-011633","json":"https://secwatch.observer/filing/0001140361-24-011633.json","markdown":"https://secwatch.observer/filing/0001140361-24-011633.md","text":"https://secwatch.observer/filing/0001140361-24-011633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/0001140361-24-011633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/ef20023378_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:35:20.586610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18b60eb785cfa701a86ecd6904e60ffa24b3ca3b","claim":"Nuwellis, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $2.6 million, net income net loss attributable to common shareholders of $7.9 million, EPS loss of $2.24 per basic and diluted common share.","evidence_excerpt":"the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: ● Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenue of $8.9 million, a 4% increase over 2022. ● Fourth quarter pediatric revenue grew 35% year over year; 28% increase in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/0001140361-24-011633-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$2.6 million"},{"label":"Net income","value":"net loss attributable to common shareholders of $7.9 million"},{"label":"EPS","value":"loss of $2.24 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}